Auto Injection Technologies LLC v. Novo Nordisk A/S: Voluntary Dismissal in Medicament Injection Device Patent Case

Case Overview

The Parties

The Patents at Issue

Two patents formed the basis of this infringement action:

• • US9,387,294 B2 — Directed to auto-injection device technology, broadly covering mechanical and functional aspects of self-injection systems.
• • US10,201,662 B2 — A continuation or related patent extending protection across complementary injection device claim sets.

Both patents address engineering mechanisms central to modern medicament delivery systems, including those used in insulin pens, biologics injectors, and similar drug administration devices widely deployed in chronic disease management.

Legal Representation

Plaintiff: Peter Lambrianakos and Vincent J. Rubino III of Fabricant LLP (NY)

Defendant: Deron R. Dacus of The Dacus Firm PC

Litigation Timeline & Procedural History

The plaintiff filed in the Eastern District of Texas — a deliberate and strategically significant choice. Despite recent efforts to redistribute patent cases nationally, the Eastern District under Chief Judge Rodney Gilstrap remains a preferred jurisdiction for patent assertion entities due to its established patent litigation infrastructure, experienced judiciary, and plaintiff-favorable procedural familiarity.

The case resolved before Novo Nordisk filed any responsive pleading — no answer, no motion to dismiss, and no summary judgment motion had been submitted. This procedural posture is critical: under Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, a plaintiff may voluntarily dismiss without a court order if the defendant has not yet answered or moved for summary judgment, and the dismissal is without prejudice unless stated otherwise.

The court accepted and acknowledged the dismissal on September 12, 2025, while explicitly directing the clerk to maintain the lead case (No. 2:25-cv-00377) as open, confirming that this action was one component of a broader multi-defendant litigation strategy.

The Verdict & Legal Analysis

Outcome

The case closed via voluntary dismissal without prejudice pursuant to Rule 41(a)(1)(A)(i). No merits determination was reached. No damages were awarded. No injunctive relief was granted or denied. Each party was ordered to bear its own costs, expenses, and attorneys’ fees — a standard condition under this procedural mechanism.

The dismissal without prejudice is legally significant: Auto Injection Technologies LLC retains the right to refile these same claims against Novo Nordisk in the future, subject to applicable statutes of limitations and any strategic recalibrations.

Verdict Cause Analysis

Because dismissal occurred before substantive litigation commenced, no claim construction rulings, validity determinations, or infringement findings were issued. The court made no legal conclusions regarding the scope of US9,387,294 B2 or US10,201,662 B2, nor did it assess whether Novo Nordisk’s injection devices fell within the asserted patent claims.

The strategic calculus behind this early exit likely reflects one or more of the following dynamics:

• • Licensing negotiations: Early dismissals in NPE litigation frequently accompany settlement or licensing discussions occurring outside the public record.
• • Claim mapping reassessment: Upon closer analysis of Novo Nordisk’s specific products, plaintiff’s counsel may have identified claim coverage gaps warranting a strategic retreat and potential claim refinement.
• • Resource reallocation: With a parallel lead case (No. 2:25-cv-00377) still active, the plaintiff may have prioritized litigation resources on more viable defendants.
• • Defendant’s pre-answer posture: Novo Nordisk’s defense team at The Dacus Firm may have communicated a vigorous defense strategy — including potential IPR petitions at the USPTO — prompting the plaintiff to reassess its litigation calculus before incurring significant costs.

Legal Significance

While this case produced no precedential ruling, its procedural trajectory carries instructive value:

• • Rule 41 as a strategic instrument: The availability of cost-free early dismissal under Rule 41(a)(1)(A)(i) makes it a low-risk retreat mechanism for patent plaintiffs, particularly in multi-defendant campaigns where selective enforcement is common.
• • Multi-case coordination: The deliberate structure of a “Member Case” and “Lead Case” framework signals coordinated litigation strategy — a pattern increasingly scrutinized by courts and defendants alike.
• • No estoppel created: A dismissal without prejudice creates no claim or issue preclusion, preserving the plaintiff’s full arsenal for future assertion against Novo Nordisk or similarly situated parties.

Industry & Competitive Implications

The medical device and pharmaceutical delivery sector sits at a complex intersection of high-value innovation and aggressive patent assertion. Auto-injection devices — central to the delivery of insulin, GLP-1 receptor agonists, and biologic therapies — represent a commercially critical technology area where patent rights carry significant market leverage.

Novo Nordisk’s position in this space, particularly given its blockbuster GLP-1 product portfolio (including Ozempic® and Wegovy®), makes it a high-profile target for patent assertion campaigns. The early dismissal here does not eliminate future risk; the “without prejudice” nature of the exit means reassertion remains possible.

For companies developing or commercializing medicament injection devices, this case underscores several competitive intelligence points:

• • Patent family monitoring around auto-injection mechanisms is essential, particularly as continuation applications mature into issued patents.
• • IPR as a defensive tool remains one of the most effective strategies for dismantling NPE assertion campaigns before district court litigation escalates.
• • The Eastern District of Texas continues to attract injection device and pharmaceutical patent cases, warranting ongoing jurisdictional risk assessment for companies with exposure in this space.

Licensing activity in the auto-injector patent space is expected to remain robust, driven by the rapid commercial growth of injectable biologic therapies and the corresponding expansion of patent portfolios targeting delivery device innovations.

Frequently Asked Questions

What patents were involved in Auto Injection Technologies LLC v. Novo Nordisk A/S?

The case involved US Patent No. 9,387,294 B2 (Application No. 13/498,620) and US Patent No. 10,201,662 B2 (Application No. 14/782,667), both directed to medicament injection device technology.

What was the basis for dismissal in Case No. 2:25-cv-00376?

Plaintiff Auto Injection Technologies LLC filed a voluntary dismissal without prejudice under Rule 41(a)(1)(A)(i) before Novo Nordisk filed any responsive pleading, resulting in court acceptance of the dismissal with each party bearing its own costs.

Could this case be refiled against Novo Nordisk?

Yes. A dismissal without prejudice does not bar future litigation on the same patents and claims, subject to applicable statutes of limitations.